Product/Composition:- | Zuclopenthixol Short-acting Intramuscular Injection |
---|---|
Strength:- | 50 mg/mL |
Form:- | Short-acting Intramuscular Injection |
Reference Brands:- | Clopixol-Acuphase® |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Zuclopenthixol short-acting IM injection is a typical antipsychotic that works by blocking dopamine D2 receptors, helping to rapidly reduce symptoms of acute psychosis and agitation. It is primarily used in emergency settings to calm aggressive or severely disturbed patients with schizophrenia or related psychotic disorders, offering quick symptom control
Zuclopenthixol short-acting intramuscular injection, commonly used in acute psychosis and agitation, is not currently approved by the FDA in the United States but is available in several EU markets under Clopixol-Acuphase. In the EU, it follows EMA regulatory standards for parenteral antipsychotics, requiring GMP compliance, stability data, and clinical justification for emergency psychiatric use. U.S. registration would require a detailed regulatory strategy, including an IND or 505(b)(2) approach. To explore other dosage forms, strengths, and dossier-ready Zuclopenthixol IM injection products, visit Pharmatradz.com — your trusted global B2B platform for API and finished formulations.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications